NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY,
The board of directors of Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) and the Company’s principal owners,
· The offer is comprised of an offer to the general public in
· The Offer comprises a maximum of 17,055,267 B shares: a maximum of 6,475,994 newly-issued B shares offered by the Company; a maximum of 4,741,435 existing B shares sold by former Bactiguard bond-holders who have offset their bonds against Bactiguard B shares; and a maximum of 5,837,838 existing B shares offered by the Principal Owners.
· The Principal Owners have issued an over-allocation option of an additional maximum of 1,705,527 existing B shares, corresponding to 10 per cent of the total number of B shares covered by the Offer, to compensate for any over-allocation that may occur in conjunction with the Offer
· The Offer price is expected to be set within the range of
· The total value of the Offer is
· The acceptance period for the Offer is
· Bactiguard’s board of directors has prepared a prospectus in contemplation of the Offer. The prospectus has been approved and registered by the
Quote by Johan Rugfelt, CEO of Bactiguard:
”Bactiguard is a highly specialised and highly profitable med-tech company. Its business concept is to prevent healthcare-related infections, reduce the use of antibiotics and save lives through the development and manufacture of healthcare products. We offer patented and well proven technology which builds on a Swedish technology. We have worked in recent years to develop our own product portfolio and build a global network of distributors. The final pieces are falling into place with Bactiguard’s IPO, because it gives us the financial strength that we need to truly realise the powerful growth we see in our future.”
”We know there are many investors who want to participate in the growth journey we have before us. Healthcare-related infections are the third leading cause of death of the Western world, after cancer and heart/vascular disease. In other words, there is an enormous need for our products. With this IPO, we as existing principal owners can maintain our long-term commitment to the company while putting Bactiguard in the best possible position to take advantage of growth opportunities.”
Background and rationale
Bactiguard is a Swedish medtech company that prevents healthcare-related infections by developing and manufacturing products for the medical industry. The Company’s infection-preventing technology is unique and helps reduce healthcare costs and the use of antibiotics. Bactiguard -coated urinary catheters are market leading in the US and
Today, the Company has sales in nine countries and a licence agreement with Bard that covers the
The Company’s objective is to continue to grow the business by strengthening the sales and marketing organisation, developing products to complement the current BIP portfolio and entering into more licence agreements. Bactiguard has identified several interesting product lines to which the Company can apply its coating and create products that are close to the current product portfolio. Product lines that are not as close to the Company’s current product portfolio will be covered mainly by licence agreements with leading market players in the specific product area. The Company’s goal is to sign two to three new licence agreements during the next five years and to expand into new markets:
· The Company has on
· An important step towards the expansion into new markets was taken when a panel of experts at the
It has been determined that a change to the Company’s capital structure is necessary to capitalise on existing growth opportunities. Ahead of the Offer and the listing of the Company’s B share on NASDAQ OMX Stockholm, the Company offered bondholders the option of converting bonds to shares in the Company in order to reduce future interest expenses and strengthen the Company’s capital structure. Holders of bonds totalling a nominal amount of
Taken together, the set-off issue and the net proceeds from the new share issue generate financial flexibility to guarantee a sustainable capital structure for the Company in the long term. The decrease in interest costs and the net proceeds from the new share issue will also be used to finance the Company’s growth.
The Offer and the IPO will broaden the Company’s shareholder base and provide the Company access to Swedish and international capital markets. A liquid share, priced on the market, also increases opportunities to use the share to finance acquisitions.
The Company’s board of directors deems that a listing of the Company’s B share on NASDAQ OMX Stockholm will attract increased attention from existing and potential customers, employees, investors and the media. A listing of the Company’s B share is also expected to draw greater attention to the global problems of spiralling healthcare costs, the spread of multi-resistant bacteria and the effect of healthcare -associated infections.
The Offer in brief
The Offer is comprised of an offer to the general public in
The Principal Owners have undertaken to offer an additional maximum of 1,705,527 existing B shares, corresponding to 10 per cent of the total number of B shares covered by the Offer, to compensate for any over -allocation that may occur in conjunction with the Offer. Based on full subscription to the Offer, Bactiguard will receive an injection of approximately
The Offer price is expected to be set within the range of
Bactiguard’s board of directors has prepared a prospectus in contemplation of the Offer. The prospectus has been approved and registered by the
The prospectus and application form are available at any
Indicative time schedule
· Publication of prospectus:
· Acceptance period for institutional investors:
· Acceptance period for general public in
· Announcement of final Offer price:
· First trading day for the Company’s B share on NASDAQ OMX Stockholm:
· Settlement day for general public:
· Settlement day for institutional investors:
This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Bactiguard Holding AB (the “Company”) in any jurisdiction where such offer or sale would be unlawful and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions.
In any EEA member state, other than
Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in
This announcement does not constitute a prospectus and nothing herein contains an offering of securities. No one should purchase or subscribe for any securities in the company, except on the basis of information in any prospectus published by the Company in connection with the potential offering and admission of such securities to trading and official listing on NASDAQ OMX Stockholm. Copies of any such prospectus will, following publication, be available on the website of the Company.
Matters discussed in this release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe”, “expect”, “anticipate”, “intends”, “estimate”, “will”, “may”, “continue”, “should”, and similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this release speak only as at its date, and are subject to change without notice.
Bactiguard Holding AB (publ) is required to disclose the above information under the provisions of the Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 20.00 CET on 9 June 2014. For further information, please contact:
Johan Rugfelt - CEO firstname.lastname@example.org +46 708 724 739
Fredrik JÄrrsten - CFO email@example.com +46 72 550 00 89
Cecilia EdstrÖm - Director of Communications firstname.lastname@example.org 46 722 262 328 Bactiguard Bactiguard is a Swedish medtech company with a business concept of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Most Popular Stories
- Illinois Issues Fracking Rules
- Americans Still Pessimistic Despite Economic Growth
- Detroit Muslim Conference Stirs Controversy
- Canada, Russia Go to War (on Twitter)
- Echeveste Steps Down, Perez Steps Up at VPE
- Startups Offer Smartphone Banking Apps
- Hip-Hop Takes Up Ferguson Cause
- 'Longmire' Cancelled, Looks for New Network
- Clippers Deal Started With 2 Numbers
- Immigration Delay Throws Both Parties a Curve